During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

U.S. net revenue from Briumvi grew by more than 230% year over year to $83.3 million. Total revenue for Q3 of $83.9 million surpassed analysts' expectations of $81.7 million. Diluted earnings per ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024, prior guidance of $290 to $300 million for full ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, ...

TG Therapeutics Inc (TGTX) reports over 230% year-over-year revenue growth, raises full-year guidance, and outlines future ...

Reports Q3 revenue $83.88M, consensus $81.71M. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The ...

TG Therapeutics reported Q3 results, including “solid” Briumvi U.S. net product revenue up $83.3M, up 15% quarter over quarter, the analyst tells investors in a research note. The firm ...